Literature DB >> 19427109

Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?

Guido Dalbagni.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427109     DOI: 10.1016/j.eururo.2009.04.041

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  5 in total

1.  Bladder cancer: meta-analysis of BCG versus mitomycin C--a deeper insight?

Authors:  Andreas Böhle
Journal:  Nat Rev Urol       Date:  2010-01       Impact factor: 14.432

Review 2.  Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.

Authors:  Homayoun Zargar; Jonathan Aning; Joseph Ischia; Alan So; Peter Black
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

3.  The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation.

Authors:  Kyung Won Seo; Byung Hoon Kim; Choal Hee Park; Chun Il Kim; Hyuk Soo Chang
Journal:  Korean J Urol       Date:  2010-03-19

4.  Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.

Authors:  Stefanie Schmidt; Frank Kunath; Bernadette Coles; Desiree Louise Draeger; Laura-Maria Krabbe; Rick Dersch; Samuel Kilian; Katrin Jensen; Philipp Dahm; Joerg J Meerpohl
Journal:  Cochrane Database Syst Rev       Date:  2020-01-08

5.  Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy.

Authors:  Vincenzo Serretta; Francesco Sommatino; Cristina Scalici Gesolfo; Vito Franco; Giuseppe Cicero; Rosalinda Allegro
Journal:  Urol Ann       Date:  2015 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.